無料プレビュー

Takeda Pharmaceutical Company Limited (TAK) · New York Stock Exchange

プロフィール

Takeda Pharmaceutical Co Ltd is a global R&D-driven biopharmaceutical company that discovers and delivers treatments across gastrointestinal and inflammation, neuroscience, oncology, plasma-derived therapies, and vaccines. Principal marketed products include ENTYVIO for inflammatory bowel disease, TAKHZYRO for hereditary angioedema, immunoglobulin therapies, and oncology medicines such as ADCETRIS and NINLARO. The company operates through regional business units in the U.S., Japan, Europe, and emerging markets including China, with a geographically diversified manufacturing and research footpr

主要指標

株価: $18.52 (+0.82%)
時価総額: 589億ドル
PER（今期予想）: 47.4
PBR: 1.2
配当利回り: 1.66%
52週レンジ: $12.99 – $19.10
業種: Healthcare / Drug Manufacturers - Specialty & Generic
上場: New York Stock Exchange
構成銘柄: —

比較会社: LLY Eli Lilly and Company、MRK Merck & Co., Inc.、AZN AstraZeneca PLC、AMGN Amgen Inc.、PFE Pfizer Inc.、BMY Bristol-Myers Squibb Company、SNY Sanofi、TEVA Teva Pharmaceutical Industries Limited

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-29 · 更新: 2026-10-09